R01 CA204419/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2016	2
2017	1
2018	1
2019	3
2020	4
2021	7
2022	4
2024	0

1

Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. Amouzegar A, et al. Cancers (Basel). 2021 May 30;13(11):2695. doi: 10.3390/cancers13112695. Cancers (Basel). 2021. PMID: 34070756 Free PMC article. Review.

2

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.

Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Guo ZS, et al. J Immunother Cancer. 2019 Jan 9;7(1):6. doi: 10.1186/s40425-018-0495-7. J Immunother Cancer. 2019. PMID: 30626434 Free PMC article. Review.

3

Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.

Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Dai E, et al. Mol Cancer. 2021 Dec 20;20(1):171. doi: 10.1186/s12943-021-01464-x. Mol Cancer. 2021. PMID: 34930302 Free PMC article. Review.

4

STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.

Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. Chelvanambi M, et al. J Immunother Cancer. 2021 Feb;9(2):e001906. doi: 10.1136/jitc-2020-001906. J Immunother Cancer. 2021. PMID: 33526609 Free PMC article.

5

IL-36 Signaling in the Tumor Microenvironment.

Chelvanambi M, Weinstein AM, Storkus WJ. Chelvanambi M, et al. Adv Exp Med Biol. 2020;1240:95-110. doi: 10.1007/978-3-030-38315-2_8. Adv Exp Med Biol. 2020. PMID: 32060891 Free PMC article. Review.

6

STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.

Filderman JN, Appleman M, Chelvanambi M, Taylor JL, Storkus WJ. Filderman JN, et al. Front Immunol. 2021 May 13;12:690105. doi: 10.3389/fimmu.2021.690105. eCollection 2021. Front Immunol. 2021. PMID: 34054879 Free PMC article. Review.

7

Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.

Fecek RJ, Storkus WJ. Fecek RJ, et al. Immunotherapy. 2016 Oct;8(10):1205-18. doi: 10.2217/imt-2016-0071. Immunotherapy. 2016. PMID: 27605069 Free PMC article. Review.

8

Finding the right help in the tumor microenvironment.

Filderman JN, Storkus WJ. Filderman JN, et al. J Clin Invest. 2022 Jun 15;132(12):e161052. doi: 10.1172/JCI161052. J Clin Invest. 2022. PMID: 35703176 Free PMC article.

9

Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO.

Weinstein AM, Storkus WJ. Weinstein AM, et al. Front Immunol. 2016 Aug 9;7:301. doi: 10.3389/fimmu.2016.00301. eCollection 2016. Front Immunol. 2016. PMID: 27555845 Free PMC article. Review.

10

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.

Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, Rose A, DeMark M, Karapetyan L, Taylor JL, Chelvanambi M, Fecek RJ, Filderman JN, Looney TJ, Miller L, Linch E, Lowman GM, Kalinski P, Butterfield LH, Tarhini A, Tawbi H, Kirkwood JM. Storkus WJ, et al. J Immunother Cancer. 2021 Nov;9(11):e003675. doi: 10.1136/jitc-2021-003675. J Immunother Cancer. 2021. PMID: 34782430 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year